HIV-1 p-17 peptide fragments, compositions containing and method

Details HIV-1 p-17 peptide fragments, compositions containing and method HIV-1 p-17 peptide fragments, compositions containing and method

1997-03-26

2000-08-29

Stucker, Jeffrey

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

530300, 530325, 530326, 530327, 530826, 4241841, 4241851, 4241861, 4241881, 4242081, 514 2, A61K 3800

Patent

active

06111068&

ABSTRACT:
Peptide fragments of the p17 gag protein of HIV-1 from Clade C of from about 30 to about 50 amino acids, including the region extending from position 75 to position 129, raise antibodies recognizing other subtypes, including Clade A, Clade B, Clade E as well as peptides of non-coextensive but overlapping portions of the p17 gag protein. DNA sequences can be used to encode for the peptides of interest. An example of the Clade C peptide of this invention is a peptide having about 30 to about 32 amino acids taken consecutively from a part or the entirety of the following sequence:

REFERENCES:
patent: 4983387 (1991-01-01), Goldstein et al.
patent: 5019510 (1991-05-01), Wain-Hobson et al.
patent: 5556744 (1996-09-01), Weiner et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
Roitt, I. Essential Immunology, Sixth Edition, Blackwell Scientific Publications, Boston, MA, pp. 173-178., 1988.
Kleid et al. Annals NY Acad. Sci. 413: 23-30., 1983.
Broekhuijsen et al. H, /gen. Virol. 68: 3137-3143., 1987.
Kuwano et al. J. Exp. Med. 169: 1361-1371., Apr. 1989.
Sarin, et al. Science 232:1135 (1986).
Naylor, et al. Proc. Nat. Acad. Sci. 84:2951 (1981).
Brander, et al. Clin. Exp. Immunol. 101:107 (1995).
Dibrino, et al. J. Immunol. 154(2) :620 (1994).
Gazzard, et al. Vaccine Res. 1:129 (1992).
Sarin, et al. Vaccine Res. 3:495 (1994).
Kahn, et al. AIDS Res. Hu. Retroviruses 8:1321 (1992).
Naylor, et al. Int. J. Immunopharm 13(Suppl) :117 (1991).
Sarin, et al. Cell. Molec. Biol. 41:401 (1995).
Kahn, et al. Abstract 13 International AIDS Conf.--Jul. 1996.
Talmadge, et al. Clin. Immunol. Meeting, New Orleans--Jun. 1996.
Jiang, et al. J. AIDS 5:382 (1992).
Naylor, et al. Nature 326:549 (1987).
Wahren, et al. J. AIDS 4:448 (1989).
Broliden, et al. Clin. Exp. Immunol. 76:216 (1989).
Papsidero, et al. J. Virol. 63:267 (1989).
Boucher, et al. Clin. Lab. Anal. 4:43 (1990).
Zimmerman, et al. Vaccine Res. 5:91 (1996a).
Zimmerman, et al. Vaccine Res. 5:103 (1996b).
Palker, et al. Proc. Nat. Acad. Sci. 85:1932 (1988).
Clerici, et al. Immuno. Today 14:107 (1993).
Johnson, et al. J. Exp. Med. 176:961 (1992).
Berzofsky, J. Acquire Immun. Deficiency Syndroms 4:451 (1991).
Coates, et al., AIDS Vaccine Predictions. Nature. Apr. 9. 1987, vol. 326, pp. 549-550.
Harrer, et al., HIV-Specific CTL-Response in Healthy Long-Term . . . , IXth Intl. Conf. On AIDS, Berlin, Jun. 1993, Abstract No. POA22-0484, p. 215.
Geysen, et al., Cognitive Features of Continuous Antigenic Determinants, J. Mol. Recog. 1988, Vol. 1, No. 1, pp. 32-41.

Affiliated with

Also associated with

Rating

HIV-1 p-17 peptide fragments, compositions containing and method does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV-1 p-17 peptide fragments, compositions containing and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 p-17 peptide fragments, compositions containing and method will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1251111